Navigation Links
Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function

CAMBRIDGE, Mass., Oct. 6, 2011 /PRNewswire/ -- Galenea Corp., a leader in the rapidly emerging field of synaptic transmission, today announced the publication of a paper in PLoS ONE demonstrating the development and validation of the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, Galenea's proprietary technology that enables high throughput screening of synaptic function directly on cultured primary neurons.  Changes in synaptic function are now believed to play a central role in many psychiatric, neurological and neurodegenerative diseases.  The MANTRA system can identify both novel drug targets and compounds that modulate disease-related synaptic dysfunction and is expected to yield new mechanism-based therapeutics for schizophrenia, Alzheimer's disease, autism, epilepsy, Huntington's disease and other CNS disorders. The paper appeared in the online October 5, 2011 edition of PLoS ONE.

David Gerber, PhD, Vice President of CNS Research at Galenea, commented, "Unbiased phenotypic screens of synaptic function using our MANTRA system should lead to breakthrough therapies for a number of debilitating disorders associated with synaptic dysfunctions.  As an illustration of this potential, we have already used MANTRA to discover a new class of pro-cognitive compounds and are using this unique screening technology to progress this novel chemotype through in-house lead optimization."  

Current techniques for studying synaptic physiology are both labor intensive and low throughput, making the dissection of this complex biological process very challenging. For the first time in a peer-reviewed journal, Galenea documents the critical advances necessary for the development of a robust high-throughput synaptic function drug screening assay.  The MANTRA system is capable of operating with exquisite sensitivity, precision, uniformity, and reproducibility. This capacity is exemplified in the manuscript by data from a set of pharmacologically defined compounds.  Screening with MANTRA demonstrated that a number of these compounds mediate their pharmacological effects by specific and previously unknown actions on presynaptic function. The extension of the MANTRA system to genomic screening should uncover new drug targets that will impact not only basic neuroscience research but also drug discovery and development.

"This publication highlights the pioneering work performed by my collaborators at Galenea," stated Timothy Ryan, PhD, Professor of Biochemistry at Weill Cornell Medical College and a co-author of the paper.  "The MANTRA system is a major technological achievement and has significant applications for advancing our understanding of the synaptic dysfunctions associated with many CNS disorders."

About Galenea

Galenea is a leader in the rapidly emerging field of synaptic transmission (ST), the process by which neurons communicate with each other.  Dysfunctions in ST are now widely believed to play a central role in many psychiatric, neurological and neurodegenerative diseases, and modulators of ST therefore have the potential to yield breakthrough treatments. Galenea has developed an innovative ST drug discovery platform that integrates three components: MANTRA™, a high throughput, proprietary screening technology to identify a new generation of small molecule modulators of synaptic transmission; in vivo models using integrated EEG measures of animal behavior to more reliably determine CNS drug efficacy; and human EEG biomarkers, developed in tandem with and informed by our animal EEG data to greatly enhance CNS drug development.   The company is advancing a novel pro-cognitive program derived from the platform and the approach can be extended to address multiple CNS disorders.  Based in Cambridge, MA, Galenea has assembled a compelling scientific team, balancing academic aptitude with industry experience and entrepreneurship.  For more information about Galenea, please visit the company's website at

SOURCE Galenea Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntingtons Disease
2. Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration
3. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
4. Express Scripts Announces Revised 2011 Financial Guidance
5. Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®
6. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
7. Cyberonics Announces Investment in ImThera Medical
8. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2012 Earnings Release Date and Teleconference
9. Clinical Care Options Announces Addition of Database to CCO inPractice™ Point-of-Care Resource
10. ConvaTec Announces Acquisition of Farnhurst Medical
11. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
Post Your Comments:
(Date:11/25/2015)... 2015  Today AVACEN Medical announced the issue of United States patent ... Adjustment ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific ... Photo - ... ... ...
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor ... Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) ... nominated by the public, will receive special recognition throughout 2016 as part of ...
(Date:11/25/2015)... ... 25, 2015 , ... Privately owned Contract Development and Manufacturing ... its current state of the art research, development and manufacturing facility outside of ... manufacturing capacity as well as to support its clients’ growing research and development ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of ... weight gain, cold hands, and dry skin. But many people who find their cholesterol ... exercise regimen instead of their thyroid, especially if they don’t have any of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
Breaking Medicine News(10 mins):